Literature DB >> 26181771

Association Between Parkinson Disease and Risk of Cancer in Taiwan.

Pei-Ying Lin1, Shih-Ni Chang2, Tzu-Hung Hsiao3, Bo-Tsang Huang4, Ching-Heng Lin3, Pan-Chyr Yang4.   

Abstract

IMPORTANCE: Parkinson disease (PD) has been reported to be associated with a general reduced risk of cancer. These studies were mainly carried out in Western populations and little was known about associations in East Asians.
OBJECTIVE: To analyze the association between PD and risk of cancer. DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, the data were obtained from the Taiwan National Health Insurance Research Database, which contained information on approximately 24.7 million insured individuals. The cohort included individuals with newly diagnosed as having PD between 2004 and 2010. An age- and sex-matched systematic random-sampling method was used for subject selection in the reference non-PD cohort. Multivariate Cox proportional hazard regression analysis was used to determine the effects of PD on the risks of cancer, as shown by hazard ratios (HRs) with 95% CIs. MAIN OUTCOMES AND MEASURES: The Taiwan Population Census and National Cancer Registry Databases were used to identify patients with cancer. The last follow-up date was December 31, 2012.
RESULTS: In 62 023 patients with PD, the HR for all subsequent cancers combined was 1.58 (95% CI, 1.50-1.65). Of the 19 types of cancer, Parkinson disease was not associated with breast, ovarian, or thyroid cancers. Increased HRs were found in the remaining 16 cancers, including malignant brain tumors (HR, 3.42; 95% CI, 1.84-6.38), gastrointestinal tract cancers (esophageal [HR, 1.81; 95% CI, 1.28-2.57], stomach [HR, 1.59; 95% CI, 1.30-1.94], colorectal [HR, 1.47; 95% CI, 1.31-1.65], liver [HR, 1.89; 95% CI, 1.67-2.14]; gallbladder [HR, 1.73; 95% CI, 1.16-2.57], and pancreas [HR, 1.48; 95% CI, 1.09-2.02]) (P < .05 for all comparisons), lung cancers (HR, 1.56; 95% CI, 1.38-1.76), some hormone-related cancers (uterine [HR, 1.83; 95% CI, 1.12-3.01], cervical [HR, 1.36; 95% CI, 1.05-1.76], and prostate [HR, 1.80; 95% CI, 1.52-2.13; P < .05 for all comparisons), urinary tract cancers (kidney and bladder cancers; HRs, 1.59 and 1.99, respectively; P < .001 for both comparisons), lymphoma and/or leukemia (HR, 1.62; 95% CI, 1.31-2.01), melanoma (HR, 2.75; 95% CI, 1.35-5.59), and other skin cancers (HR, 1.81; 95% CI, 1.46-2.23). For hepatocellular carcinoma, the highest HR resided in the 50- to 59-year-old group (HR, 2.57; 95% CI, 1.7-3.89). CONCLUSIONS AND RELEVANCE: Our study concludes that PD is is associated with most cancers in Taiwan. Further studies are needed to clarify whether our findings can be applied to other East Asian populations. The differences between our study and most previous cohorts suggest the importance of ethnicity and environmental exposures in disease pathogenesis.

Entities:  

Mesh:

Year:  2015        PMID: 26181771     DOI: 10.1001/jamaoncol.2015.1752

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


  29 in total

1.  Associations between cancer and Parkinson's disease in U.S. elderly adults.

Authors:  D Michal Freedman; Jincao Wu; Honglei Chen; Eric A Engels; Lindsey R Enewold; Neal D Freedman; James J Goedert; Ralph W Kuncl; Mitchell H Gail; Ruth M Pfeiffer
Journal:  Int J Epidemiol       Date:  2016-03-17       Impact factor: 7.196

2.  Parkinson's disease and colorectal cancer risk-A nested case control study.

Authors:  Ben Boursi; Ronac Mamtani; Kevin Haynes; Yu-Xiao Yang
Journal:  Cancer Epidemiol       Date:  2016-05-24       Impact factor: 2.984

3.  Risk of Parkinson's disease after colectomy: longitudinal follow-up study using a national sample cohort.

Authors:  Young-Ju Kim; Chang-Min Lee; Seongheon Kim; Jae-Won Jang; Seo-Young Lee; Seung-Hwan Lee
Journal:  J Neurol       Date:  2019-11-05       Impact factor: 4.849

Review 4.  Exploring the nexus of Alzheimer's disease and related dementias with cancer and cancer therapies: A convening of the Alzheimer's Association & Alzheimer's Drug Discovery Foundation.

Authors:  Heather M Snyder; Tim Ahles; Stuart Calderwood; Maria C Carrillo; Honglei Chen; Chung-Chou H Chang; Suzanne Craft; Philip De Jager; Jane A Driver; Howard Fillit; David Knopman; Michael Lotze; Mary C Tierney; Suzana Petanceska; Andrew Saykin; Sudha Seshadri; Diana Shineman; Mary Ganguli
Journal:  Alzheimers Dement       Date:  2016-12-18       Impact factor: 21.566

Review 5.  Understanding the role of dopamine in cancer: past, present and future.

Authors:  Christopher E Grant; Amy L Flis; Bríd M Ryan
Journal:  Carcinogenesis       Date:  2022-06-27       Impact factor: 4.741

6.  Adeno-associated virus-delivered alpha synuclein inhibits bladder cancer growth via the p53/p21 signaling pathway.

Authors:  Zhengcun Wu; Chengxing Xia; Chao Zhang; Donghong Tang; Feineng Liu; Yitian Ou; Jiahong Gao; Hongkun Yi; Delin Yang; Kaili Ma
Journal:  Cancer Gene Ther       Date:  2022-01-21       Impact factor: 5.854

7.  The Relationship between Parkinson Disease and Brain Tumor: A Meta-Analysis.

Authors:  Rong Ye; Ting Shen; Yasi Jiang; Lingjia Xu; Xiaoli Si; Baorong Zhang
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

8.  Measuring intratumor heterogeneity by network entropy using RNA-seq data.

Authors:  Youngjune Park; Sangsoo Lim; Jin-Wu Nam; Sun Kim
Journal:  Sci Rep       Date:  2016-11-24       Impact factor: 4.379

Review 9.  The associations between Parkinson's disease and cancer: the plot thickens.

Authors:  Danielle D Feng; Waijiao Cai; Xiqun Chen
Journal:  Transl Neurodegener       Date:  2015-10-26       Impact factor: 8.014

10.  Parkinson's disease and cancer: a systematic review and meta-analysis of over 17 million participants.

Authors:  Xinyuan Zhang; David Guarin; Niyaz Mohammadzadehhonarvar; Xiqun Chen; Xiang Gao
Journal:  BMJ Open       Date:  2021-07-02       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.